FDA-Approved GLP-1 Drugs for Weight Loss in 2026

The FDA has now approved five GLP-1 medications specifically for chronic weight management — three injectable, two oral. Every other GLP-1 used for weight loss (Ozempic, Mounjaro) is being prescribed off-label — which is legal but doesn't qualify for weight-management-specific savings programs.

The official approved list for weight loss, as of 2026:

FDA-approved GLP-1 medications for weight management

The eligibility criteria on all five are the same:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related condition (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, etc.)

Each drug has its own dosing, side-effect profile and average trial results.

Saxenda (liraglutide)

The first GLP-1 ever approved for weight management.

• Approved (weight): 2014
• Maker: Novo Nordisk
• Form: Daily subcutaneous injection
• Dose range: 0.6 → 3.0 mg/day (weekly titration)
• Trial weight loss: ~8% body weight at 56 weeks (SCALE trial)
• Cash-pay: ~$1,349/month list

Pros: Long track record; daily injection has a shorter half-life if you want to stop quickly. Cons: Daily dosing is an adherence burden; lower average weight loss than newer weekly options.

Wegovy (semaglutide)

The breakthrough that made GLP-1 weight loss mainstream.

• Approved (weight): 2021
• Maker: Novo Nordisk
• Form: Weekly subcutaneous injection
• Dose range: 0.25 → 2.4 mg/week, plus Wegovy HD 7.2 mg
• Trial weight loss: ~15% body weight at 68 weeks (STEP-1)
• Cash-pay: ~$1,349/month list; $349/month via NovoCare direct
• Additional approvals: Cardiovascular risk reduction (SELECT, 2024); MASH with moderate-to-advanced fibrosis (2024–2025)

Strongest cardiovascular evidence in the class. Now also approved for MASH (metabolic-associated steatohepatitis).

Zepbound (tirzepatide)

The current weight-loss leader by trial average.

• Approved (weight): 2023
• Maker: Eli Lilly
• Form: Weekly subcutaneous injection (pens, KwikPen, LillyDirect vials)
• Dose range: 2.5 → 15 mg/week
• Trial weight loss: ~21% body weight at 72 weeks (SURMOUNT-1)
• Cash-pay: ~$1,299/month (pens); $349–$499/month via LillyDirect vials
• Additional approvals: Moderate-to-severe obstructive sleep apnea in adults with obesity (2024)

The dual GLP-1 / GIP agonist mechanism is what makes tirzepatide outperform single-receptor semaglutide on average weight loss.

Wegovy oral (semaglutide pill)

Same active molecule as injectable Wegovy, in a pill.

• Approved: December 2025
• Maker: Novo Nordisk
• Form: Daily oral tablet
• Dose range: 0.25 → 25 mg/day (much higher than injection because of poor oral bioavailability)
• Trial weight loss: ~13% body weight at 64 weeks (OASIS program)
• Cash-pay: $149/month for 1.5 mg and 4 mg (intro pricing through Aug 2026, then $199); $199/month for 0.25 / 0.5 mg start doses
• How to take it: Empty stomach, first thing in the morning, 30 minutes before any food, drink (except water), or other medication

The empty-stomach requirement is a real adherence challenge for people already taking medications like levothyroxine or omeprazole.

Foundayo (orforglipron)

The first oral small-molecule GLP-1 — easier to take than oral Wegovy.

• Approved: 2026 (under FDA National Priority Voucher program)
• Maker: Eli Lilly
• Form: Daily oral tablet
• Dose range: 0.8 → 17.2 mg/day (six strengths)
• Trial weight loss: ~12% body weight at the highest dose; ~27 lb average vs ~2 lb placebo in 72-week trial
• Cash-pay: From $149/month via LillyDirect
• Insurance options: ~$25/month with commercial insurance + Lilly discount card; ~$50/month with Medicare Part D starting July 2026

Foundayo's edge: it can be taken any time of day, with or without food — unlike oral Wegovy. The trade-off is somewhat lower average weight loss than the injectables.

What's NOT FDA-approved for weight loss (but commonly used off-label)

These GLP-1 drugs are FDA-approved for type 2 diabetes, not weight loss. Doctors can prescribe them off-label for weight loss, and many do, but:

• They don't qualify for weight-loss-specific savings programs
• Insurance generally won't cover them for off-label weight loss
• The cash-pay price applies in full

The big off-label ones:

• Ozempic (semaglutide, weekly injection) — approved for T2D, not weight management
• Mounjaro (tirzepatide, weekly injection) — approved for T2D, not weight management
• Rybelsus (semaglutide, daily oral 3-14 mg) — approved for T2D
• Trulicity (dulaglutide, weekly injection) — approved for T2D
• Victoza (liraglutide, daily injection) — approved for T2D
• Byetta / Bydureon (exenatide) — approved for T2D

For the full picture, see GLP-1 drugs list.

Pipeline: drugs heading for weight-management approval

• Retatrutide (Eli Lilly) — triple agonist GLP-1/GIP/glucagon. Phase 3 TRIUMPH program reading through 2026; NDA expected late 2026; weight-management approval projected 2027–2028. Phase 2 results showed ~24% weight loss. See our Retatrutide guide.
• Survodutide (Boehringer Ingelheim / Zealand) — dual GLP-1/glucagon agonist; Phase 3 for obesity and MASH
• CagriSema (Novo Nordisk) — combination of cagrilintide + semaglutide; Phase 3 read-outs 2026
• Pemvidutide (Altimmune) — dual GLP-1/glucagon; clinical development for obesity and MASH

How to choose among FDA-approved weight-loss GLP-1s

1. Coverage: What does your insurance cover for weight management?
2. Dosing preference: Injection (weekly preferred for adherence) or pill (Foundayo > oral Wegovy on convenience)
3. Comorbidities: Heart disease → Wegovy (SELECT CV outcomes data). OSA → Zepbound (OSA approval).
4. Cost: Manufacturer programs differ by drug. See GLP-1 cost.

For the head-to-head ranking by efficacy, see best GLP-1 for weight loss.

FAQ

Is Ozempic FDA-approved for weight loss? No. Ozempic is FDA-approved for type 2 diabetes. It's commonly prescribed off-label for weight loss but the weight-loss indication belongs to Wegovy (the higher-dose semaglutide brand).

Is Mounjaro FDA-approved for weight loss? No. Mounjaro is FDA-approved for type 2 diabetes. The weight-management brand of tirzepatide is Zepbound.

What's the newest FDA-approved GLP-1 for weight loss? Foundayo (orforglipron), approved in 2026. Before that, oral Wegovy in December 2025.

Will my insurance cover an FDA-approved weight-loss GLP-1? Coverage varies. Many employer plans now cover Wegovy or Zepbound for patients meeting BMI criteria; coverage requires prior authorization in most cases.

When will retatrutide be FDA-approved? Projected late 2027 to early 2028 if Phase 3 trials read out as expected and the FDA review proceeds on standard timelines.

This article is for educational purposes only and is not medical advice. FDA approvals and indications change. Verify current FDA-approved indications and labeling at the relevant FDA drug page or with a qualified healthcare professional.